Mer­ck’s Keytru­da fails more prostate and lung can­cer PhI­II tri­als

Mer­ck’s can­cer drug be­he­moth, the an­ti-PD1 Keytru­da, has failed two more Phase III tri­als in the hard-to-treat prostate can­cer set­ting and in a cer­tain lung can­cer, per a Tues­day up­date.

That marks more than half a dozen Phase III flops in the past 12 months for the drug, which won its first ap­proval in 2014 and has gen­er­at­ed dozens of bil­lions in rev­enue for Mer­ck, ac­count­ing for $20.9 bil­lion in glob­al sales last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER